Targets › PBPB
5 programs from 3 companies in 6 trials: 3 Phase 4, 3 Phase 3; Infectious disease; next expected readout Dec 2028.
Open in Phaseline: the race on PBPB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Melbourne | Cefazolin Bacterial penicillin-binding protein inhibitor | PBPB | Phase 4 | Staphylococcus Aureus Bacteremia | Dec 2028 |
| University of Melbourne | Penicillin G Bacterial penicillin-binding protein inhibitor | PBPB | Phase 4 | Staphylococcus Aureus Bacteremia | Dec 2028 |
| Carilion Clinic | Cephalexin Bacterial penicillin-binding protein inhibitor | PBPB | Phase 4 | Surgical Site Infection | – |
| Tampere University Hospital | Cloxacillin Penicillin-binding protein inhibitor | PBPB | Phase 3 | Infection | Dec 2028 |
| Tampere University Hospital | Piperacillin Bacterial penicillin-binding protein inhibitor | PBPB | Phase 3 | Infection | Dec 2028 |
Infection (3) Staphylococcus Aureus Bacteremia (2) Surgical Site Infection (1)
small molecule (5)
University of Melbourne (2) Tampere University Hospital (2) Carilion Clinic (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.